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ABSTRACT 
Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options 
and poor prognosis. TNBC is usually diagnosed at a relatively young age and is characterized by high risk of developing 
metastases. Some epigenetic regulation of gene expression is associated with TNBC. Expression of microRNAs (miRNAs) 
can serve as a potential tool for identifying critical biomarkers in TNBC.
The aim of our study is to examine expression of selected miRNAs in TNBC and to assess the relationship between miRNA 
expression and clinicopathological factors.
Material and methods: Expression levels of 19 selected miRNAs were compared between cancerous and normal breast 
tissues by use of qPCR method. We have evaluated the relationship between the expression level of miRNAs and clinico-
pathological factors such as: age, tumor size and lymph node status.
Results: We found that in TNBC tissues, when compared with normal breast tissues, the expression of miR-190a, miR-
136-5p and miR-126-5p was significantly reduced (p = 0.0041, p = 0.0007, p = 0.0007, respectively) whereas expression of 
miR-135b-5p and miR-182-5p was significantly increased (p = 0.0194, p = 0.0041, respectively). We found a linear trend for 
tumor size and expression of miR-126-5p (p = 0.0296) and miR-135b-5p (p = 0.0241).
Conclusions: Our study confirms that miRNA expression profile is dysregulated in TNBC patients compared to healthy 
controls. MiR-190a, miR-136-5p, miR-126-5p, miR-135b-5p and miR-182-5p may be associated with development and 
progression of TNBC.
Key words: TNBC, microRNA expression, biomarkers
Ginekologia Polska 2017; 88, 10: 530–536
Corresponding author:
Izabela Zawlik
Department of Genetics, Faculty of Medicine, University of Rzeszow 
Laboratory of Molecular Biology, Center for Innovative Research in Medical and Natural Sciences University of Rzeszow
Warzywna 1A, 35-959 Rzeszow, Poland
tel: +48 17 851 68 10, e-mail: izazawlik@yahoo.com
INTRODUCTION
Breast cancer is a heterogeneous disease and a major 
cause of female mortality [1]. Triple-negative breast cancer 
(TNBC) is defined by a lack of expression of estrogen recep-
tor (ER), progesterone receptor (PR) and of human epider-
mal growth factor receptor-2 (HER2) [2]. TNBC accounts 
for approximately 15–25% of all breast cancer types and 
is an aggressive histological subtype. There exist following 
TNBC subtypes: basal or BRCA-related, apocrine, normal-like 
and other rare subtypes including a neuroendocrine TNBC 
[3]. Subtyping of TNBC is necessary to choose an optimal 
molecular-based therapy [4]. TNBC is mostly diagnosed in 
patients at a relatively young age and is characterized by 
frequent metastasis [5, 6]. Patients with TNBC have increased 
risk of relapse and tend to resist to chemotherapies [7]. Thus, 
further subtyping with more individual therapy adjustments 
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could improve patients’ survival. One of the new potentially 
useful biomarkers in oncology is miRNA [8].
miRNAs are short non-coding RNAs of 19–25 nucleotides 
in length. They regulate gene expression post-transcription-
ally by pairing with complementary nucleotide sequences 
in the 3’-UTRs of specific mRNA targets [9]. Deregulation 
of specific miRNAs associated with carcinogenesis causes 
changes in their expression and function. This way some 
acquire the features of oncogenes while others become 
tumor suppressors [10]. Since 1993, when the first miRNA 
lin-4 was discovered, the knowledge about miRNAs has been 
greatly expanded. The regulatory role of miRNA was deter-
mined in many cellular pathways involved in cell division, 
differentiation, morphogenesis, metabolism and apopto-
sis [11]. Studies carried out on various types of cancers made 
clear that miRNA expression is an important factor for the 
carcinogenesis. TNBC is a heterogeneous subtype of breast 
cancer that has limited treatment options [12]. Thus, miRNA 
studies may be useful for developing new therapeutic strate-
gies. It has been reported that numerous cellular signaling 
pathway abnormalities occur in TNBC [13]. There has been 
increasingly more evidence supporting the role of miRNAs 
in cell signaling pathways of triple-negative breast cancer 
but its clinical significance is still unclear [14, 15]. 
OBJECTIVES
The aim of our study is to examine the expression of 
selected miRNAs in TNBC tissues in comparison with normal 
breast tissue and to assess the relationship between miRNA 
expression and some clinical features such as: age of onset, 
tumor size and lymph node status.
MATERIAL AND METHODS
The study was conducted under Institutional Review 
Board protocol #RNN/226/11/KE/13/12/2011 at Medical 
University of Lodz. All patients gave written informed con-
sent. We included in this study 11 TNBC female patients 
and 3 healthy age-matched women controls. All of 11 ex-
amined patients exhibit an invasive ductal histology and 
a third histologic grade. One of the patients had evidence 
of distant metastases in lungs and liver. Between December 
2011 and April 2012 specimens were collected at the Can-
cer Center with ultrasound-guided 14-gauge core needle 
biopsy (ultra-automatic biopsy instrument Pro-Mag TM, 
Angiotech) from 11 female patients with either inoperable 
locally advanced breast cancer or with large operable tumor 
suitable for down-staging. Further specimens were obtained 
from 3 healthy age-matched women controls (breast reduc-
tion procedures). Four to five specimens were obtained from 
each lesion. Half of samples were frozen immediately at 
–80°C while the rest was parafﬁn embedded and reviewed 
by breast pathology specialist in the Department of Pathol-
ogy. Estrogen receptor (ER) and progesterone receptor (PR) 
status were determined by immunohistochemistry (IHC) 
using the Allred score. Human epidermal growth factor 
receptor 2 (HER2) status was evaluated by immunohisto-
chemistry or by ﬂuorescence in situ hybridization. Samples 
were considered ER or PR negative if less than 1% of the 
tumor cells were immunoreactive. Samples were considered 
HER2 negative with IHC 1+ staining or with a score of 2+ 
and no HER2 gene amplification when tested by FISH. TNBC 
was diagnosed when result was ER, PR and HER2 negative.
MicroRNA expression analysis by use of qPCR
Selection of 19 miRNAs was performed on the basis 
of previous reports in the literature and the miRNA da-
tabase. In the total of 14 breast tissue samples (11 from 
TNBC and 3 from healthy controls) we analyzed 19 mi- 
RNAs: hsa-miR-512-5p, hsa-miR-190a, hsa-miR-200b-3p, 
hsa-miR-622, hsa-miR-346, hsa-miR-148b-5p, hsa-miR-449a, 
hsa-miR-1255b-5p, hsa-miR-203a, hsa-miR-577, hsa-miR-
93-5p, hsa-miR-126-5p, hsa-miR-423-5p, hsa-miR-129-5p, 
hsa-miR-193b-5p, hsa-miR-182-5p, hsa-miR-136-5p, hsa-
miR-191-5p and hsa-miR-135b-5p. Hsa-miR-103a-3p and 
hsa-miR-107 were chosen for normalization, which was 
further validated by NormFinder algorithm. RNA was iso-
lated using miReasy Mini Kit 50 (Qiagen, Valencia, CA, USA). 
10 ng RNA sample was reverse transcribed in 10 µl reactions 
using the miRCURY LNA™ Universal RT microRNA PCR, Poly-
adenylation and cDNA synthesis kit (Exiqon, Copenhagen, 
Denmark). Each RT was performed in duplicates. cDNA was 
diluted 100 × and assayed in 10 µL PCR reactions according 
to the protocol for miRCURY LNA™ Universal RT microRNA 
PCR; each miRNA was assayed once by qPCR on the micro-
RNA Ready-to-Use PCR, Custom Pick&Mix panel. Negative 
controls excluding templates from the reverse transcription 
reaction were processed and profiled in a similar fashion. 
Amplification was performed in a LightCycler® 480 Real-Time 
PCR System (Roche, Basel, Switzerland). The amplification 
curves were analyzed using the Roche LC software, both for 
determination of Cp (by the 2nd derivative method) and for 
melting curve analysis.
Data analysis 
The assay efficiency was determined by means of analy-
sis of the amplification curves using algorithms similar to the 
LinReg software. Individual reactions that gave efficiency 
of < 1.6 were excluded from the dataset. The efficiencies 
ranged between 1.8 and 2.1. All assays were inspected for 
distinct melting curves and the Tm was confirmed to be 
within known specifications for the assay. It was important 
that assays with 5 Cp’s less compared to negative control 
be detected and those with Cp < 37 be included in the 
data analysis. Data that failed to reach such criteria was 
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excluded from further analysis. The stability of miRNAs was 
measured by NormFinder software [16]. For normalization of 
the data we have used the average of hsa-miR-103a-3p and 
hsa-miR-107, which proved to be the most stable normal-
izer (according to E normalization). (Stability value for best 
combination of such pair equals 0.045). The formula used 
to calculate the normalized Cp values was:
Normalized delta Cp = average Cp (hsa-miR-103a-3p 
and hsa-miR-107) — assay Cp (sample).
Target gene selection
In order to find miRNA target genes we have searched 
miRTarBase 6.0 — a database that manually collects ex-
perimental data about miRs-genes interactions. We selected 
only those interactions concerning human miRNAs and 
human gene targets proved by strong experimental evi-
dence method (Reporter assay, Western blot or qPCR techni- 
que) [17]. 
Statistical analysis
Continuous variables were presented as mean values 
with respective standard deviations. Selected miRNA ex-
pression levels in TNBC tissues and normal tissues were 
compared using a Student t-test after adjustment for Benja-
mini-Hochberg multiple comparison (False Discovery Rate). 
Assessment of correlation between a particular miRNA ex-
pression and the patients’ age was performed with Pearson 
correlation. Association between tumor size (T stage) and 
lymph node status (N stage) was verified by linear trend 
analysis. For multidimensional data — Principal Compo-
nent Analysis and Unsupervised Hierarchical Clustering was 
performed. Statistical analysis was done with MultiExperi-
ment Viewer (MeV) software (Dana Farber, Boston, USA) and 
STATISTICA 10.0 software (Statsoft, Tulsa, OK, USA). P values 
lower than 0.05 were considered as statistically significant.
RESULTS
Ten common miRNAs were identified in all samples with 
an average of 18 miRNAs detectable per sample. MicroRNAs 
detected in all control samples and in more than 8 TNBC 
samples were further analyzed. Thus, 14 miRNAs have been 
included in the Principal Component Analysis (PCA) (Fig. 1) 
and in the two-way hierarchical clustering of miRNAs (Fig. 2). 
Samples seem to cluster based on group information pro-
vided; however, sample 9 falls closer to the normal tissue 
samples than to the TNBC (Fig. 1 and Fig. 2).
The analysis revealed that five miRNAs (miR-136-5p, 
miR-126-5p, miR-182-5p, miR-190a, miR-135b-5p) have 
a significantly different expression in TNBC tissue when 
compared with healthy controls (Table  1). We observed 
a significant down-regulation of miR-190a, miR-136-5p 
and miR-126-5p (dCp –5.95 ± 0.91 vs. –4.36 ± 0.28, 
p = 0.0041, dCp –4.03 ± 1.21 vs. –0.94 ± 0.39, p = 0.0007, 
dCp –3.61 ± 1.18 vs. –1.06 ± 0.31, p = 0.0007, respectively). 
The following in turn were up-regulated: miR-135b-5p and 
miR-182-5p (dCp –3.13 ± 1.44 vs. –7.08 ± 0.91, p = 0.0194, 
dCp –3.48 ± 1.13 vs. –5.79 ± 0.41, p = 0.0041, respectively) 
(Table 1). The association between tumor size (T), lymph 
node status (N) and patient’s age and miRNAs expression 
is presented in Table 2. 
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Figure 1. The Principal Component Analysis plot. PCA was performed 
on all samples and on those assays with a count of at least 12 
(missing values are substituted by group averages). The normalized 
(dCp) values have been used for the analysis. The analysis was 
performed on 3 normal breast tissues (green color) and 11 TNBC 
tissues (blue color)
Figure 2. Heat map and unsupervised hierarchical clustering. 
The clustering is performed on all samples and on those assays 
with a count of at least 12. The color scale illustrates the relative 
expression level of microRNA across all samples: red color represents 
an expression level above mean, green color represents expression 
lower than the mean. The normalized (dCp) values have been used 
for the analysis
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We noticed a significant linear trend for T value and ex-
pression levels of miR-126-5p (p = 0.0296) and miR-135b-5p 
(p = 0.0241) (Figure 3). Moreover, miR-126-5p correlated pos-
itively with expression of miR-136-5p (r = 0.61, p = 0.0444) 
and negatively with miR-135b-5p (r = (–0.72), p = 0.0124).
Moreover, we searched for 5 selected miRNA validated 
target genes. MiRTarBase has showed associations with 
50 genes with strong evidenced for being targets for one 
of the 5 miRNAs (Table 3). 
Table 1. Selected miRNAs expressed in normal breast tissues and in TNBC tissues
miRNA names Count
Average dCp ± standard deviation
p-value FDR*
TNBC patients Healthy controls
hsa-miR-136-5p 14 –4.03 ± 1.21 –0.94 ± 0.39 7.34E-05 0.0007
hsa-miR-126-5p 14 –3.61 ± 1.18 –1.06 ± 0.31 8.89E-05 0.0007
hsa-miR-182-5p 14 –3.48 ± 1.13 –5.79 ± 0.41 0.0008 0.0041
hsa-miR-190a 14 –5.95 ± 0.91 –4.36 ± 0.28 0.0010 0.0041
hsa-miR-135b-5p 14 –3.13 ± 1.44 –7.08 ± 0.91 0.0061 0.0194
hsa-miR-577 12 –3.57 ± 0.34 –4.37 ± 0.29 0.0333 0.0888
hsa-miR-423-5p 14 –3.17 ± 0.54 –2.70 ± 0.15 0.0415 0.0948
hsa-miR-93-5p 14 –0.40 ± 1.04 –1.14 ± 0.05 0.0488 0.0977
hsa-miR-203a 12 –6.44 ± 1.38 –7.65 ± 0.78 0.1547 0.2751
hsa-miR-148b-5p 14 –10.65 ± 0.48 –11.09 ± 0.33 0.1878 0.3005
hsa-miR-191-5p 14 –3.00 ± 0.28 –3.23 ± 0.23 0.2984 0.3979
hsa-miR-449a 13 –11.03 ± 0.75 –11.21 ± 0.82 0.7935 0.8521
hsa-miR-200b-3p 14 –2.70 ± 0.76 –2.88 ± 0.85 0.7989 0.8521
hsa-miR-193b-5p 13 –8.09 ± 0.59 –8.08 ± 0.58 0.9832 0.9832
*False Discovery Rate
Table 2. P values for association of miRNA expression with patient 
age, tumor size (T stage) and lymph node status (N stage)
miRNA name T N Age
hsa-miR-136-5p 0.0681 0.4447 0.4627
hsa-miR-126-5p 0.0296 0.7999 0.4627
hsa-miR-182-5p 0.1491 0.1186 0.7473
hsa-miR-190a 0.5595 0.8718 0.6667
hsa-miR-135b-5p 0.0241 0.5629 0.7678
[For T and N, p value was calculated with linear trend whereas for Age with 
Spearman correlation] 
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Figure 3. Association between hsa-miR-126-5p (A), hsa-miR-135b-5p (B) and tumor size (T stage)
534
Ginekologia Polska 2017, vol. 88, no. 10
www. journals.viamedica.pl/ginekologia_polska
DISCUSSION
We found that expression of miR-182-5p and miR-135b-5p 
was significantly increased while that of miR-190a, miR-136-5p 
and miR-126-5p was significantly reduced in TNBC tissues 
in comparison with normal breast tissues. We observed 
a linear trend for T stage and expression of miR-126-5p 
and miR-135b-5p. In the study we did not find a significant 
association between the expression level of miRNAs and 
patients’ age of onset or lymph node status.
MiR-182-5p belongs to the miR-183 family and miR-182-5p 
is encoded on chromosome 7q31-34 [18]. Medimegh et al. 
(2014) examined expression of miR-182 in the following 
three groups: TNBC, NTNBC (Non Triple Negative Breast 
Cancer; Luminal A, Luminal B and HER2 positive patients) 
and healthy controls. The analysis showed significantly high-
er expression of miR-182 in TNBC with respect to NTNBC 
cases. Moreover, the expression of miR-182 in both cancer 
groups was still higher than in healthy controls [19]. In present 
study we confirm the increased expression of miR-182-5p 
in TNBC patients.
It was reported that miR-182-5p is important for the 
tumor development as miR-182 has been associated with 
DNA damage repair, cell proliferation and apoptosis [20]. 
MiR-182 inhibits expression of BRCA1 [21] that is responsible 
for repair of double-stranded DNA damage (DSBs) in homolo-
gous recombination (HR). Deficiency of BRCA1 protein leads 
to activation of other than HR repair mechanisms, the inef-
ficiency of which causes genetics instability [22]. Moreover, 
silencing of miR-182-5p resulted in increase of BRCA1 levels 
and induction of resistance to radiation and to treatment 
with poly (ADP-ribose) polymerase 1 (PARP-1) inhibitors [21]. 
This phenomenon could be explained by activation of BR-
CA1-related tumor cell repair mechanism. Therefore, tumor 
cells do not activate the apoptotic pathway and become 
more resistant to treatment [23]. Medimegh et al. have no-
ticed a significant association of lymph node metastases with 
miR-182 overexpression in TNBC of Tunisian population [19]. 
In present study we did not find any significant association 
between miR-182-5p expression and lymph node status, 
which is consistent with results of Krishnan et al. (2013) [24]. 
In our study we also noticed a significantly higher ex-
pression of miR-135-5p. The knowledge about miR-135-
5p function in TNBC development is limited. Up-regulated 
miR-135b was so far identified only in basal like subtype 
of breast cancer and estrogen-negative patients. In turn, 
miR-135b expression was correlated with worse survival 
of breast cancer patients and metastasis status [25]. In the 
study of Muñoz-Rodríguez et al. (2015) it was showed that 
miR-135b expression levels are higher in patients with breast 
cancer in early postpartum period compared to late post-
partum period. Moreover, the miR-135b gene expression 
and its DNA methylation had a significant inverse correla-
tion [26]. MiR-135b has been showed to be up-regulated 
in breast cancer [27], which is consistent with our study. 
Moreover miR-135b promotes cellular proliferation and 
disrupts the cell cycle of breast cancer cells by regulating 
LATS2 [27]. In our study we show a linear trend for T stage 
and expression of miR-135b-5p; we observe lower expres-
sion in higher tumor size.
Our study also showed that miR-190a, miR-126-5p and 
miR-136-5p are down-regulated in TNBC tissues. Hao et al. 
(2014) brought attention to the role of miR-190a in suppres-
sion of tumor metastasis via interaction with VEGF-mediated 
tumor angiogenesis [28]. In breast cancer, overexpression 
of miR-190a has inhibited the cell migration and invasive-
ness. Moreover, miR-190a expression in primary breast car-
cinomas correlated with overall survival [29]. Nevertheless, 
the role of miR-190a in breast cancer biology is still unclear.
We also report down-regulated miR-126-5p expression 
in TNBC. A different study has revealed that miR-126 plays 
a tumor-suppressor role and impedes the metastasis of 
non-small cell lung cancer by inhibiting tumor growth and 
cell invasion [30]. Moreover, miR-126 target genes include 
a variety of oncogenic factors such as ADAM9 [31]. The 
loss of miR-126 expression was associated with poor distal 
metastasis-free survival of breast cancer patients [32]. In our 
study there is linear trend for miR-126; we observed higher 
miR-126 levels in bigger tumor size.
When it comes to miR-136, it has been shown that it 
is up-regulated in lung cancer [33]. In turn, Zhao et al. ob-
Table 3. Human target genes for significantly dysregulated human microRNAs in a TNBC from miRTarBase, confirmed by strong evidence 
validation methods (Reporter assay, Western blot, qPCR)
MicroRNA name Target gene name
hsa-miR-136-5p MTDH, BCL2, PPP2R2A
hsa-miR-126-5p SLC45A3, PTPN7, ADAM9, MMP7, CXCL12, MYC
hsa-miR-182-5p
CDKN1A, FOXO3, MTSS1, FOXO1, RARG, MITF, ADCY6, CLOCK, TSC22D3, CREB1, FGF9, NTM, CYLD, BCL2, CCND2, PDCD4, 
PFN1, SNAI2, RECK, SMAD4, FOXF2, FLOT1, PTEN, GSK3B, ANUBL1, SATB2, CHL1, CADM1, TP53INP1, ATF1, BARD1, CREB5, 
RAD17, TP53BP1, CHEK2, CDKN1B, SMARCD3, TCEAL7, FBXW7, LRRC4, NDRG1, THBS1, ULBP2, BDNF, EP300
hsa-miR-190a-5p CDKN1B, PHLPP1, KCNQ5, MARK2, IGF1
hsa-miR-135b-5p APC, KLF4, MAFB, CASR, PPP2R5C, SMAD5, LZTS1, MID1, MTCH2, ACVR1B, BMPR2, TGFBR1, IBSP, BGLAP, RUNX2, SP7
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served low expression of miR-136 in patients with chem-
oresistant epithelial ovarian cancer [34]. Generally, it has 
been demonstrated that miR-136 was down-regulated in 
TNBC [35], which is consistent with our study. Yan et al. 
showed that suppression of tumor invasion and metastasis 
by miR-136 was mediated through targeting RASAL2, which 
plays oncogenic role in TNBC. Moreover, expression of miR-
136 was negatively correlated with WHO grades in TNBC [35].
In summary, the present study confirms the aberrant 
expression of miRNAs in TNBC patients when compared to 
healthy tissues. Such results indicate the influence of epi-
genetic factors in the development of TNBC. We have dem-
onstrated a dysregulated expression of 5 miRNAs in TNBC 
tissues. Moreover, we have found a linear trend for tumor 
size and expression levels of miR-126-5p and miR-135b-5p.
Yet, it is necessary to verify our results on a larger popula-
tion. The present study provides further experimental data 
for these candidate miRNAs in order to aid the identifica-
tion of reliable molecular diagnostic markers of TNBC in 
the future. 
Acknowledgments
This study was supported by the grant no. 2011/01/ 
/B/NZ4/03345 of the National Science Centre, Poland,. 
The study was performed within the project ’Centre for 
Innovative Research in Medical and Natural Sciences’ 
realized by University of Rzeszow, co-financed within 
Regional Operational Program for the Podkarpackie 
Province for the years 2007-2013, contract number UDA-
-RPPK.01.03.00-18-004/12-00. The study was partly sup-
ported by funds from the University of Rzeszow, Faculty of 
Medicine. We would like to thank PhD Beata Małachowska 
for assistance with statistical analysis. 
Author disclosure statement
None.
REFERENCES
1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014; 
64(1): 9–29, doi: 10.3322/caac.21208, indexed in Pubmed: 24399786.
2. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined 
by five biomarkers has superior prognostic value than triple-negative 
phenotype. Clin Cancer Res. 2008; 14(5): 1368–1376, doi: 10.1158/1078-
0432.CCR-07-1658, indexed in Pubmed: 18316557.
3. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical 
need. Oncologist. 2011; 16 Suppl 1: 1–11, doi: 10.1634/theoncolo-
gist.2011-S1-01, indexed in Pubmed: 21278435.
4. Godfrey SS, Moses MM, Rorie CJ. Cancer Associated MicroRNAs are 
Differentially Expressed in Triple Negative Breast Cancer and Normal 
Breast Cells. Int J Surg Res. 2015: 4–78.
5. Boyle P. Triple-negative breast cancer: epidemiological considerations 
and recommendations. Ann Oncol. 2012; 23 Suppl 6: vi7–v12, doi: 
10.1093/annonc/mds187, indexed in Pubmed: 23012306.
6. Anders C, Carey LA. Understanding and treating triple-negative breast 
cancer. Oncology (Williston Park). 2008; 22(11): 1233–9; discussion 1239, 
indexed in Pubmed: 18980022.
7. O’Reilly EA, Gubbins L, Sharma S, et al. The fate of chemoresistance in 
triple negative breast cancer (TNBC). BBA Clin. 2015; 3: 257–275, doi: 
10.1016/j.bbacli.2015.03.003, indexed in Pubmed: 26676166.
8. D’Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. 
Int J Mol Sci. 2013; 14(11): 22202–22220, doi: 10.3390/ijms141122202, 
indexed in Pubmed: 24284394.
9. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005; 
11(12): 1753–1761, doi: 10.1261/rna.2248605, indexed in Pubmed: 16314451.
10. Dvinge H, Git A, Gräf S, et al. The shaping and functional consequences 
of the microRNA landscape in breast cancer. Nature. 2013; 497(7449): 
378–382, doi: 10.1038/nature12108, indexed in Pubmed: 23644459.
11. Ha TY. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Dis-
ease. Immune Netw. 2011; 11(3): 135–154, doi: 10.4110/in.2011.11.3.135, 
indexed in Pubmed: 21860607.
12. Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast 
cancer and its clinical implications. Curr Opin Oncol. 2011; 23(6): 566–577, 
doi: 10.1097/CCO.0b013e32834bf8ae, indexed in Pubmed: 21986848.
13. Hsu YH, Yao J, Chan LC, et al. Definition of PKC-α, CDK6, and MET as 
therapeutic targets in triple-negative breast cancer. Cancer Res. 2014; 
74(17): 4822–4835, doi: 10.1158/0008-5472.CAN-14-0584, indexed in 
Pubmed: 24970481.
14. Avery-Kiejda KA, Braye SG, Mathe A, et al. Decreased expression of key 
tumour suppressor microRNAs is associated with lymph node metas-
tases in triple negative breast cancer. BMC Cancer. 2014; 14: 51, doi: 
10.1186/1471-2407-14-51, indexed in Pubmed: 24479446.
15. Matamala N, Vargas MT, González-Cámpora R, et al. MicroRNA deregula-
tion in triple negative breast cancer reveals a role of miR-498 in regu-
lating BRCA1 expression. Oncotarget. 2016; 7(15): 20068–20079, doi: 
10.18632/oncotarget.7705, indexed in Pubmed: 26933805.
16. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantita-
tive reverse transcription-PCR data: a model-based variance estimation 
approach to identify genes suited for normalization, applied to bladder 
and colon cancer data sets. Cancer Res. 2004; 64(15): 5245–5250, doi: 
10.1158/0008-5472.CAN-04-0496, indexed in Pubmed: 15289330.
17. Chou CH, Chang NW, Shrestha S, et al. miRTarBase 2016: updates to the 
experimentally validated miRNA-target interactions database. Nucleic 
Acids Res. 2016; 44(D1): D239–D247, doi: 10.1093/nar/gkv1258, indexed 
in Pubmed: 26590260.
18. Wang F, Zhong S, Zhang H, et al. Prognostic Value of MicroRNA-182 
in Cancers: A Meta-Analysis. Dis Markers. 2015; 2015: 482146, doi: 
10.1155/2015/482146, indexed in Pubmed: 26063957.
19. Medimegh I, Omrane I, Privat M, et al. MicroRNAs expression in triple 
negative vs non triple negative breast cancer in Tunisia: interaction with 
clinical outcome. PLoS One. 2014; 9(11): e111877, doi: 10.1371/journal.
pone.0111877, indexed in Pubmed: 25369070.
20. Wei Q, Lei R, Hu G. Roles of miR-182 in sensory organ development and 
cancer. Thorac Cancer. 2015; 6(1): 2–9, doi: 10.1111/1759-7714.12164, 
indexed in Pubmed: 26273328.
21. Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 
impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011; 41(2): 
210–220, doi: 10.1016/j.molcel.2010.12.005, indexed in Pubmed: 21195000.
22. Severson TM, Peeters J, Majewski I, et al. BRCA1-like signature in triple 
negative breast cancer: Molecular and clinical characterization reveals 
subgroups with therapeutic potential. Mol Oncol. 2015; 9(8): 1528–1538, 
doi: 10.1016/j.molonc.2015.04.011, indexed in Pubmed: 26004083.
23. de Ruijter TC, Veeck J, de Hoon JPJ, et al. Characteristics of triple-negative 
breast cancer. J Cancer Res Clin Oncol. 2011; 137(2): 183–192, doi: 
10.1007/s00432-010-0957-x, indexed in Pubmed: 21069385.
24. Krishnan K, Steptoe AL, Martin HC, et al. MicroRNA-182-5p targets 
a network of genes involved in DNA repair. RNA. 2013; 19(2): 230–242, 
doi: 10.1261/rna.034926.112, indexed in Pubmed: 23249749.
25. Arigoni M, Barutello G, Riccardo F, et al. miR-135b coordinates progres-
sion of ErbB2-driven mammary carcinomas through suppression of 
MID1 and MTCH2. Am J Pathol. 2013; 182(6): 2058–2070, doi: 10.1016/j.
ajpath.2013.02.046, indexed in Pubmed: 23623609.
26. Muñoz-Rodríguez JL, Vrba L, Futscher BW, et al. Differentially expressed 
microRNAs in postpartum breast cancer in Hispanic women. PLoS One. 
2015; 10(4): e0124340, doi: 10.1371/journal.pone.0124340, indexed in 
Pubmed: 25875827.
27. Hua K, Jin J, Zhao J, et al. miR-135b, upregulated in breast cancer, pro-
motes cell growth and disrupts the cell cycle by regulating LATS2. Int 
J Oncol. 2016; 48(5): 1997–2006, doi: 10.3892/ijo.2016.3405, indexed in 
Pubmed: 26934863.
536
Ginekologia Polska 2017, vol. 88, no. 10
www. journals.viamedica.pl/ginekologia_polska
28. Hao Y, Yang J, Yin S, et al. The synergistic regulation of VEGF-mediated 
angiogenesis through miR-190 and target genes. RNA. 2014; 20(8): 
1328–1336, doi: 10.1261/rna.044651.114, indexed in Pubmed: 24962367.
29. Chu HW, Cheng CW, Chou WC, et al. A novel estrogen receptor-microRNA 
190a-PAR-1-pathway regulates breast cancer progression, a finding 
initially suggested by genome-wide analysis of loci associated with 
lymph-node metastasis. Hum Mol Genet. 2014; 23(2): 355–367, doi: 
10.1093/hmg/ddt426, indexed in Pubmed: 24009311.
30. Yang J, Lan H, Huang X, et al. MicroRNA-126 inhibits tumor cell growth 
and its expression level correlates with poor survival in non-small cell 
lung cancer patients. PLoS One. 2012; 7(8): e42978, doi: 10.1371/journal.
pone.0042978, indexed in Pubmed: 22900072.
31. Wang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell invasion by 
targeting ADAM9. Int J Clin Exp Pathol. 2015; 8(6): 6547–6553, indexed 
in Pubmed: 26261534.
32. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human micro- 
RNAs that suppress breast cancer metastasis. Nature. 2008; 451(7175): 
147–152, doi: 10.1038/nature06487, indexed in Pubmed: 18185580.
33. Liu Xi, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an onco-
genic microRNA in mouse and human lung cancer cells by repressing 
specific tumor suppressors. J Clin Invest. 2010; 120(4): 1298–1309, doi: 
10.1172/JCI39566, indexed in Pubmed: 20237410.
34. Zhao H, Liu S, Wang G, et al. Expression of miR-136 is associated with 
the primary cisplatin resistance of human epithelial ovarian cancer. 
Oncol Rep. 2015; 33(2): 591–598, doi: 10.3892/or.2014.3640, indexed 
in Pubmed: 25482209.
35. Yan M, Li X, Tong D, et al. miR-136 suppresses tumor invasion and 
metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol 
Rep. 2016; 36(1): 65–71, doi: 10.3892/or.2016.4767, indexed in Pubmed: 
27108696.
